Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Ihre Aufgaben: Fach- und Führungsverantwortung für die Produktmanagement-Gruppe Cabling für Hochfrequenz Leitungskonfektion mit Schwerpunkt Europa Produktverantwortung für den Bereich sämtlicher Hochfrequenz Kabelassembly wie z.B. Fakra, HFM, HSD, RMC, H-MTD Marktverantwortung für internationale Automobilzulieferer & OEM Produkt- und
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Location: Germany Work Model: Remote Reports To: VP, Business Development Role Type: Full-Time, Individual Contributor Travel: Up to 25% Position Overview: The role of the Business Development Director is part of CIBT’s commercial organisation. Commercial is
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Unternehmensbeschreibung Die Deutsche Presse-Agentur (dpa) wurde 1949 gegründet und gehört zu den weltweit führenden unabhängigen Nachrichtenagenturen. dpa beliefert Medien, Unternehmen und Organisationen mit redaktionellen Angeboten. Dazu zählen Texte, Fotos, Videos, Grafiken, Hörfunkbeiträge und andere Formate. Als